This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Multiple Myeloma
and you are
over 18
years old
0
This is an early phase trial to investigate
how or whether the drug affects your body.
Show me locations

The purpose

The purpose of this study is to better understand the effects of the chemotherapy medication bortezomib on cancer cells. The investigators are therefore taking blood and bone marrow samples from patients with myeloma who are receiving bortezomib to see if the investigators can detect autophagy in the myeloma cells from the bone marrow and in immune cells in the blood. Subjects are eligible if their doctor is planning to treat them with bortezomib for the first time for their myeloma.

Provided treatments

  • Drug: Bortezomib

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01594242. The sponsor of the trial is Abramson Cancer Center of the University of Pennsylvania and it is looking for 11 volunteers for the current phase.
Official trial title:
A Phase 0 Study of Autophagy Induction After Bortezomib For Myeloma